🚀 Medial Secures Investment on Shark Tank India - Fueling the Future of Professional Social Networking. 🔥
Login

News on Medial

Healthians posts Rs 263 Cr revenue in FY25; nears breakeven

EntrackrEntrackr · 2m ago
Healthians posts Rs 263 Cr revenue in FY25; nears breakeven
Medial

Healthians posts Rs 263 Cr revenue in FY25; nears breakeven Healthians didn't manage notable growth in the fiscal year ending March 2025. However, the WestBridge-backed company narrowed its losses by 89% year on year and neared break-even during the same period. The firm’s operating revenue increased 8% year-on-year to Rs 263 crore in FY25, up from Rs 243 crore in FY24, as per its consolidated financial statements filed with the Registrar of Companies (RoC). Including non-operating income of Rs 7 crore, the company’s total income grew 7% to Rs 270 crore during the year. Cost optimisation played a key role in supporting the company’s financial recovery. Total expenses declined 8% to Rs 275 crore in FY25, compared to Rs 298 crore last year. Among the major cost heads, employee benefits, the largest expense category, dropped 13% year-on-year to Rs 104 crore in FY25 from Rs 120 crore in FY24. Cost of materials contracted 7% to Rs 54 crore. Advertising costs rose 10% to Rs 43 crore. Meanwhile, depreciation and finance costs remained stable at Rs 29 crore and Rs 15 crore, respectively. The improvement in revenue and control of key expenses helped Healthians bring down its losses sharply by 89% to Rs 5 crore in FY25 from Rs 45 crore in FY24. The firm posted positive EBITDA of Rs 32 crore in FY25 with EBITDA margin of 12.17%. Its ROCE stood at 2.73% in the same period. On a unit basis, the company spent Rs 1.05 to earn a rupee of operating revenue in FY25. The firm’s current assets increased slightly to Rs 170 crore including cash and bank balances worth Rs 49 crore in the fiscal. According to startup data intelligence platform TheKredible, Healthians has raised a total of $75 million of funding till date, having WestBridge, BEENEXT, DG Ventures and Youwecan as its lead investors. The company’s founder and CEO, Deepak Sahni owns 6.5% of the company.

Related News

Healthians achieves EBITDA breakeven with Rs 250 Cr income in FY24

EntrackrEntrackr · 1y ago
Healthians achieves EBITDA breakeven with Rs 250 Cr income in FY24
Medial

Diagnostic startup Healthians recorded a modest 8% year-on-year growth during the fiscal year ending March 2024. However, the WestBridge-backed company reduced its losses by 65% and achieved EBITDA breakeven in the same period. Healthians’s revenue from operations increased to Rs 243 crore in FY24 from Rs 224 crore in FY23, its consolidated annual results sourced from the Ministry of Corporate Affairs (MCA) show. Healthians offers at-home diagnostic services across over 250 cities and claims to have conducted more than 10 crore tests to date. Income from running laboratories for pathological tests was the primary source of revenue for Healthians which increased 8.62% to Rs 240.5 crore in FY24. The rest of the collections were from the sale of supplements, which stood at Rs 2.2 crore in the last fiscal year. Healthians also added Rs 10 crore from non-operational activities (interest income) which tallied the overall revenue to Rs 253 crore in FY24, as compared to Rs 236 crore in FY23. The Gurugram-based company allocated 40% of its overall burn to employee benefits. This cost dropped by 11.8% to Rs 120 crore in FY24 compared to Rs 136 crore in FY23. Advertising expenses also shrank over 62% to Rs 39 crore in FY24 from Rs 103 crore in FY23. The cost of material consumed, rent, Information technology, and other overheads took the overall expenditure to Rs 298 crore in FY24. The controlled spending on advertising and employee benefits helped Healthians to narrow losses by 65% to Rs 45 crore in FY24. With this, the company has achieved EBITDA breakeven in the previous fiscal (FY24). Coming to the ratios, Healthians’ ROCE and EBITDA margins improved to -20.4% and 0% (breakeven) in FY24. It spent Rs 1.23 to earn a rupee in FY24. The company has a total current assets of Rs 62 crore including the cash and bank balances of Rs 30 crore in the previous fiscal. Healthians has raised around $80 million to date including its last round of $54 million led by WestBridge in 2022. According to the startup data intelligence platform TheKredible, WestBridge is the largest external stakeholder with 25% followed by Beenext and DG Ventures. Financial stability is the primary thing that a company needs to survive. It seems like Healthians got some of the mantras to how to be constant with the scale while burning low. Achieving EBITDA breakeven for the first time will give more confidence to both founders and investors. Turning this achievement into net profits is difficult yet achievable- an approach Dr. PathLabs has been executing for many years. The next two to three years will be crucial in shaping the company's trajectory.

Healthkart’s revenue nears Rs 1,400 Cr in FY25; profit triples

EntrackrEntrackr · 2m ago
Healthkart’s revenue nears Rs 1,400 Cr in FY25; profit triples
Medial

Healthkart’s revenue nears Rs 1,400 Cr in FY25; profit triples HealthKart, a nutrition and supplement e-commerce platform, recorded a 3X year-on-year jump in profit after turning profitable in FY24. The Gurugram-based company’s sharp profit growth was steered by strong sales momentum and a controlled cost structure. Healthkart’s operating revenue grew 29% to Rs 1,313 crore in FY25 from Rs 1,021 crore in FY24, according to its consolidated financial statement sourced from the Registrar of Companies (RoC). HealthKart owns and manufactures eight nutritional brands including popular supplement brands like MuscleBlaze, The Protein Zone, TrueBasics, HKVitals, bGreen, Nouriza, and Gritzo. Sales of products formed 97% of total revenue which rose by 29% to Rs 1,277 crore in FY25. Collections from services also increased by 16% to Rs 36 crore. Notably, non-operating revenue increased to Rs 55 crore in the last fiscal year from Rs 48 crore in FY24. The cost of materials accounted for the largest share of the company’s expenditure at 49%. To the tune of scale, this cost rose 26% to Rs 623 crore in FY25 from Rs 495 crore in FY25. Advertising spend saw a sharper rise of 39% to Rs 263 crore, while commission expenses increased 22% to Rs 82 crore. In contrast, employee benefit costs declined 5% to Rs 115 crore. Overall, Healthkart managed to keep its cost growth below revenue expansion. Its total expenses rose 23% to Rs 1,273 crore in FY25 from Rs 1,032 crore in FY24. The company’s profit surged over 3X to Rs 120 crore in FY25, while its ROCE and EBITDA margin improved to 5.45% and 6.02%, respectively. On a unit basis, Healthkart spent Re 0.97 to earn a rupee of operating revenue in FY25, compared to Rs 1.01 in FY24. As of FY25, its current assets stood at Rs 971 crore including Rs 73 crore in cash and bank balances. According to startup data intelligence platform TheKredible, Healthkart has raised a total of $382 million of funding till date, having Peak XV Partners, Temasek and Sofina as its lead investors. The company’s founder and CEO, Sameer Maheshwari owns 12% of the company.

Healthians posts Rs 224 Cr revenue and Rs 184 Cr loss in FY23

EntrackrEntrackr · 1y ago
Healthians posts Rs 224 Cr revenue and Rs 184 Cr loss in FY23
Medial

Healthtech startup Healthians had targeted Rs 500 crore revenue with profits in FY23. But it seems like the company has missed this projection by a significant margin: it did not reach even the halfway mark. At the same time, its losses spiked 55%. The company’s revenue from operations increased 34.13% to Rs 224 crore in FY23 from Rs 167 crore in FY22, its consolidated financial statements filed with the Registrar of Companies show. Healthians delivers health test at-home services, extending a diverse array of health tests across 250 cities in India. According to its website, the firm has facilitated over 100 million tests since its inception in 2015. The sale of diagnostics services was the primary source of revenue for Heathians while the rest of the income came from the sale of supplements. Visit TheKredible for a detailed revenue breakup. In line with similar healthtech platforms, its employee benefits formed 32% of the overall expenditure. This cost rose by 83.8% to Rs 136 crore in FY23 from Rs 74 crore in FY22. Its advertising and promotional costs also saw an increase of 45% in FY23. The cost of materials, legal-professional, technical service, information technology, and other overheads propelled its overall expenditure by 40.9% to Rs 420 crore in FY23 from Rs 298 crore in FY22. Head to TheKredible for a complete expense breakup. Expenses Breakdown Total ₹ 298 Cr https://thekredible.com/company/healthians/financials View Full Data To access complete data, visithttps://thekredible.com/company/healthians/financials Total ₹ 420 Cr https://thekredible.com/company/healthians/financials View Full Data To access complete data, visithttps://thekredible.com/company/healthians/financials Cost of materials consumed Cost of materials consumed Employee benefit Employee benefit Information technology Information technology Legal professional Legal professional Advertising promotional Advertising promotional Cost technical services Cost technical services Others To check complete Expense Breakdown visit thekredible.com View full data Caveat: We have excluded the gain/loss of the FVTPL for both years (FY23 and FY22). With the increase in expenses outpacing the revenue growth, losses for Healthians grew 54.6% to Rs 184 crore in FY23. Its ROCE and EBITDA stood at -74% and -61.4% respectively. FY22-FY23 FY22 FY23 EBITDA Margin -56% -61.4% Expense/₹ of Op Revenue ₹1.78 ₹1.88 ROCE -27% -74% On a unit level, it spent Rs 1.88 to earn a rupee in FY23. With the Covid pandemic and its associated after effects well behind now, it’s a testing time in more ways than one for health test firms. So much so that larger diagnostic firms stopped providing splits between Covid and non-Covid testing some time ago. Established players are fighting back with a vengeance, even as customers seek more options. Hospital chains in the larger cities are also probably much more aggressive today in trying to retain their OPD business for their diagnostic clinics. As independent entities, Healthians faces the obvious issue of doctors not really recommending it or worse, discounting its test results, as we have observed in many cases. Add to that the intense competition and consequent discounting in the market today, and profits are the last thing on the mind of players. While a listed player like Dr Lal PathLabs might be more careful, others are not so worried as these seek to grab market share. More importantly, the larger players with a captive base like hospitals or even listed players have the money to invest in newer testing methods and technology. The next big market by all measures remains tier 3 and 4 cities, something that will not please Healthians again for the investments they will demand to set up a network. It is probably time to brainstorm around a clear differentiator in terms of communications, or even a test area it can count on for higher margins, for Healthians to make the next step towards sustainability.

Ixigo posts Rs 284 Cr revenue Q4 FY25; profit jumps 2.4X

EntrackrEntrackr · 8m ago
Ixigo posts Rs 284 Cr revenue Q4 FY25; profit jumps 2.4X
Medial

Ixigo released its financial results for the fourth quarter of the ongoing fiscal year (Q4 FY25) on Wednesday. The company reported a 72% growth in scale, while its year-on-year (YoY) profits increased by 2.4X during the same period. Ixigo’s revenue from operations surged 72% to Rs 284 crore in Q4 FY25 in contrast to Rs 165 crore in Q4 FY24, as per the firm’s consolidated financial results sourced from the National Stock Exchange (NSE). For the full fiscal year (FY25), Ixigo’s operating revenue increased 39% to Rs 914 crore in FY25 from Rs 656 crore in FY24. The Gurugram-based company generated the largest share (44%) of its operating revenue from train ticketing, which rose to Rs 124 crore in Q4 FY25 from Rs 94 crore in Q4 FY24. Flight and bus booking services contributed 30% and 23% to the company’s revenue, respectively. According to the company, its gross transaction value (GTV) grew 65% year-on-year to Rs 4,418 crore in the fourth quarter of FY25, as compared to Rs 2,685 crore in the same quarter of the previous year. Besides operating revenue, the firm also earned Rs 6 crore via interest and gains from financial assets during the quarter which took its total topline to Rs 290 crore in the quarter ending March 2025. Ixigo has not provided a detailed breakdown of expenses in its quarterly financial statements. However, employee benefits expenses rose by 31% YoY to Rs 46 crore. Overall, the company's total costs grew 73% to Rs 263 crore in Q4 FY25 compared to Rs 152 crore in Q4 FY24. For the full financial year ending March 2025, the firm’s total expenses rose to Rs 846 crore as against Rs 628 crore in FY24. In the end, Ixigo's net profits surged 2.4X to Rs 17 crore in Q4 FY25 from Rs 7 crore in Q4 FY24. On a fiscal basis, its net profit decreased 18% to Rs 60 crore in FY25 from Rs 73 crore in FY24. Ixigo is currently trading at Rs 167 at the end of today’s session with a total market capitalization of Rs 6,500 crore (approximately $760 million).

Pee Safe reports Rs 82 Cr revenue in FY25, nears breakeven

EntrackrEntrackr · 24d ago
Pee Safe reports Rs 82 Cr revenue in FY25, nears breakeven
Medial

Pee Safe improved its financial performance in FY25 as the company continued to scale while tightening its cost structure. The Gurugram-based firm reduced its losses by nearly 70% during the fiscal year ending March 2025. Pee Safe’s revenue from operations grew 46% to Rs 82 crore in FY25 from Rs 56 crore in FY24, as per its financial statements filed with the Registrar of Companies (RoC). Launched in 2013 by Vikas Bagaria and Srijana Bagaria, Pee Safe generates revenue primarily from sales of sanitary, personal hygiene, and intimate care products across online marketplaces, offline retail, and its direct-to-consumer channels. Revenue from these products was the sole source of revenue for the company. Cost of materials remained the largest cost component for the company, forming around 31% of total expenditure. This cost rose 29% to Rs 27 crore in FY25. Advertising and promotional spending, the second largest cost head, increased 16% to Rs 26 crore. Employee benefit expenses went up 18% to Rs 13 crore, while commission and freight costs stood at Rs 5 crore each. Overall, Pee Safe’s total expense increased 24% to Rs 86.5 crore in FY25 from Rs 70 crore in FY24. With the company’s revenue growth outpacing expense growth, Pee Safe managed to curb its losses by 69% to Rs 4 crore in FY25 from Rs 13 crore in FY24. Its ROCE and EBITDA margin stood at -46.25% and -4.15% respectively. On a unit level, the company spent Rs 1.05 to earn a rupee of operating revenue in FY25, improving from Rs 1.25 in FY24. Pee Safe’s current assets stood at Rs 24 crore, while cash and bank balances were reported at Rs 2 crore during FY25. According to TheKredible, Pee Safe has raised $13.55 million in funding to date, with Alkemi Partners as its lead investor. Its founder & CEO, Vikas Bagaria, owns 11.20% of the company. Either way, the firm is not just close to breakeven, but close to key milestones like the Rs 100 crore mark, profitability and possibly much more, if it can stay focused and deliver on its core promise.

Healthians founder Deepak Sahni steps down

EntrackrEntrackr · 3d ago
Healthians founder Deepak Sahni steps down
Medial

Snippets Healthians founder Deepak Sahni steps down Under Sahni’s leadership, Healthians has raised a total of 75 million dollars in funding to date, with WestBridge, BEENEXT, DG Ventures, and YouWeCan among its lead investors. Sahni owns 6.5 percent of the company. Gyan Vardhan 27 Jan 2026 14:06 IST Deepak Sahni, founder of health tech startup Healthians, has stepped down after a decade with the Gurugram-based company. “After spending 10 years as Founder and CEO of Healthians, I transitioned to the role of Executive Chairman in November 2023 and, over the past year, helped guide the company’s first truly professional management team. For me, Healthians will never be just a company. It has been a mission, a problem worth solving. After scaling it to a valuation of more than Rs 3,000 crore, expanding to over 300 cities, building more than 22 labs, and raising seven rounds of capital without external bankers, we have proven that diagnostics in India can be built at scale, with soul,” Sahni said in a LinkedIn post. Going forward, Sahni will focus on backing the next generation of founders through his 100 crore rupees corpus commitment. He plans to work on solving deeper problems in healthcare, support promising founders, and build new ventures with greater clarity and courage. He added that as of this month, he has stepped away from all formal executive responsibilities and will continue as a shareholder, cheering from the sidelines as the management team and investors take the company forward. Healthians’ operating revenue increased 8 percent year on year to Rs 263 crore in FY25 from Rs 243 crore in FY24, according to its consolidated financial statements filed with the Registrar of Companies. The company offers at home diagnostic services across more than 250 cities and claims to have conducted over 10 crore tests to date. Including non operating income of Rs 7 crore, Healthians’ total income grew 7% to Rs 270 crore during the year. Improved revenue and tighter cost controls helped Healthians reduce its losses sharply by 89% to Rs 5 crore in FY25 from Rs 45 crore in FY24. The firm also reported positive EBITDA of Rs 32 crore in FY25, with an EBITDA margin of 12.17%.

Ampere posts Rs 659 Cr revenue in FY25; cuts losses by 65%

EntrackrEntrackr · 18d ago
Ampere posts Rs 659 Cr revenue in FY25; cuts losses by 65%
Medial

Ampere posts Rs 659 Cr revenue in FY25; cuts losses by 65% Ampere Vehicles has shown signs of recovery as the company posted single-digit revenue growth in FY25, after the company had seen its revenue fall sharply by 46% in FY24. The company also managed to curb its losses in the same period. Ampere’s operating revenue grew 8% to Rs 659 crore in FY25 from Rs 612 crore in FY24, according to its financial statements sourced from the Registrar of Companies (RoC). Ampere, a brand under Greaves Electric Mobility, focuses on manufacturing electric scooters and three-wheeled vehicles. Sale of these products was the sole source of revenue for the company. Including other income of Rs 16 crore, Ampere’s total income rose to Rs 675 crore in FY25, compared to Rs 641 crore a year earlier. On the spending side, the cost of material accounted for 64% of the total expense. This cost rose 12% to Rs 589 crore in FY25 from Rs 527 crore in FY24. Employee benefit expenses declined 22% to Rs 79 crore, while advertising and promotional spends jumped 30% to Rs 43 crore during the year. Depreciation expenses climbed 41% to Rs 45 crore in FY25 from Rs 32 crore in FY24. Other overheads, including warranty claims, finance costs, and miscellaneous expenses, added another Rs 205 crore in FY25. Overall, total expenses increased 7% to Rs 918 crore in FY25 from Rs 857 crore in FY24. Ampere managed to cut its losses by 65% to Rs 240 crore in FY25 from Rs 691.5 crore in FY24. Its ROCE and EBITDA margin improved to -85.27% and -30.50%, respectively. On a unit basis, Ampere spent Rs 1.39 to earn every rupee of operating revenue during the year, marginally better than Rs 1.40 in FY24. As of March 2025, the company reported cash and bank balances of Rs 25 crore, while its current assets stood at Rs 263 crore. In terms of E2W sales for December, Greaves Electric Mobility retained its sixth position and sold 4,335 units with a market share of 4.66%. In comparison, the segment’s leader TVS sold 24,317 units with a market share of 26.14%. In December 2024, Ampere’s parent Greaves Electric filed its draft red herring prospectus (DRHP) with the Security Exchange Board of India (SEBI) for an initial public offering (IPO) to raise funds through a fresh issue of equity shares aggregating up to Rs 1,000 crore (approximately $119 million) and an offer for sale (OFS) of up to 18.94 crore equity shares. The firm also received a final nod from SEBI for the proposed IPO.

Redcliffe Labs posts Rs 419 Cr revenue in FY25; narrows EBITDA losses

EntrackrEntrackr · 6m ago
Redcliffe Labs posts Rs 419 Cr revenue in FY25; narrows EBITDA losses
Medial

Redcliffe Labs posts Rs 419 Cr revenue in FY25; narrows EBITDA losses Diagnostics platform Redcliffe Labs has posted a 20% increase in its operating revenue to Rs 419 crore in FY25 from Rs 350 crore in FY24 and managed to narrow its EBITDA losses, as per the company’s press release. Diagnostics platform Redcliffe Labs has posted a 20% increase in its operating revenue to Rs 419 crore in FY25 from Rs 350 crore in FY24, as per the company’s press release. The Gurugram-based firm also managed to reduce its EBITDA losses from -38% to -21% during the same period. Founded by Aditya Kandoi, Redcliffe operates a nationwide network of over 80 labs and claims to have the widest home sample collection footprint in the country. Diagnostic services contributed over 95% of the company’s revenue in FY25, with the rest coming from product sales and other operating income. The company said it diagnosed over 2.5 million cases last fiscal and continues to focus on expanding in underserved regions, with more than 70% of its testing volumes now coming from Tier II cities and beyond. On the profitability front, Redcliffe reported a gross margin of 70% in FY25 and is aiming to expand it to 74% in FY26. It has also set a revenue target of Rs 560 crore for the ongoing fiscal through organic growth and strategic acquisitions. “We are transforming lives and making diagnostics a first-line solution for millions who were previously underserved,” said Kandoi. The company plans to expand its presence to over 300 cities with 150 labs by FY28. According to startup data platform TheKredible, Redcliffe has raised $113 million to date, including a $42 million Series C round led by LeapFrog. It also acquired Bengaluru-based Celara Diagnostics in a $7 million deal. Redcliffe competes with players like PharmEasy-owned Thyrocare, Tata 1mg, and Healthians.

Gameskraft crosses Rs 4,000 Cr revenue in FY25; PAT nears Rs 1,000 Cr

EntrackrEntrackr · 4m ago
Gameskraft crosses Rs 4,000 Cr revenue in FY25; PAT nears Rs 1,000 Cr
Medial

Gameskraft crosses Rs 4,000 Cr revenue in FY25; PAT nears Rs 1,000 Cr Gameskraft’s FY25 numbers reflect strong performance before the RMG ban. The firm reported double-digit revenue growth and maintained profitability during the fiscal year. The Indian government’s recent ban on real-money gaming formats has disrupted the sector overnight, but Gameskraft’s FY25 numbers reflect strong performance before the clampdown. The firm reported double-digit revenue growth and maintained profitability during the fiscal year. Gameskraft’s revenue from operations grew 12% to Rs 3,896 crore in FY25 from Rs 3,475 crore in FY24, according to its consolidated financial statements sourced from the Registrar of Companies (RoC). Gameskraft operated popular gaming apps such as Rummy Culture, Playship, Pocket 52, RummyPrime, Ludo Culture, and Rummy Time. Its revenue (gross gaming revenue) came from platform fee or commission charged as a percentage of the buy-in fees users invest in games, which contributed Rs 3,882 crore (99.6% of operating revenue), registering a 12.2% growth. Its real estate business added Rs 11 crore, while other income sources contributed Rs 3 crore in FY25. The Bengaluru-based company made an additional Rs 113 crore from non-operating sources which pushed its total revenue to Rs 4,009 crore in FY25. On the cost side, promotional spending emerged as the single largest expense and accounted for 75% of total burn. To the tune of scale, this cost surged 58% to Rs 2,072 crore in FY25 from Rs 1,315 crore in FY24. Employee benefits, on the other hand, saw a decline of 11% to Rs 410 crore, while legal and professional fees fell 22.8% to Rs 112 crore in FY25. Overall, the company’s total expenses shot up 24% to Rs 2,766 crore in FY25 as against Rs 2,232 crore in FY24. See TheKredible for the detailed cost breakdown during the last fiscal year. Despite the jump in ad spend, Gameskraft managed to sustain profitability on the back of its strong topline and controlled costs in other areas. Its net profit stood at Rs 976 crore in FY25, slightly higher than the Rs 947 crore posted in FY24. It's worth noting that we have excluded exceptional items worth Rs 270.5 crore in the calculation of net profit of the company. Gameskraft's ROCE and EBITDA margin stood at 58.40% and 31.63%, respectively. On a unit basis, Gameskraft spent Rs 0.71 to earn a rupee of operating revenue in FY25. The company recorded current assets worth Rs 2,232 crore in FY25 which includes Rs 253 crore in cash and bank balances and Rs 1,319 crore invested in mutual funds. While Gameskraft’s FY25 numbers were unaffected, the Indian government’s new gaming law effective August 2025 has forced the company to halt its real-money operations, including shutting down “Add Cash” features and discontinuing its flagship rummy platform RummyCulture, alongside pausing its poker venture Pocket52 earlier in the year. The move, mandated by the Promotion and Regulation of Online Gaming Act, has also led Gameskraft to publicly state it will not pursue a legal challenge, instead opting for full compliance. Given that real-money gaming contributed nearly all of Gameskraft’s FY25 revenue, the ban is expected to significantly impact its business model, revenue streams, and growth trajectory going forward.

Upstox posts Rs 1,208 Cr income and Rs 215 Cr profit in FY25

EntrackrEntrackr · 6d ago
Upstox posts Rs 1,208 Cr income and Rs 215 Cr profit in FY25
Medial

Upstox posts Rs 1,208 Cr income and Rs 215 Cr profit in FY25 Stockbroking firm Upstox reported flat revenue in the fiscal year ended March 2025, but improved profitability by 21.5% to Rs 215 crore, driven largely by higher non-operating income. Upstox’s revenue from operations remained flat at Rs 945 crore in the fiscal year ended March 2025, compared to Rs 951 crore in FY24, according to its consolidated financial statements sourced from the Registrar of Companies (RoC). Upstox provides retail investors with investment options, including stocks, IPOs, futures & options (F&O), commodities, currencies, fixed deposits, peer-to-peer lending, government bonds, non-convertible debentures (NCDs), gold, and insurance. As of December 2025, Upstox has 2.08 million active clients with a market share of 4.64%. Brokerage income remained the company’s primary revenue stream at Rs 767 crore, which formed over 81% of total income. Depository operations added Rs 65 crore, while the remaining Rs 113 crore came from management services and other operating income. The company also reported Rs 263 crore in non-operating income, for which no detailed breakup was provided. Including this, the company’s total income for FY25 stood at Rs 1,205 crore. On the cost front, advertising and business promotion expenses remained the largest cost head for the stockbroking firm, accounting for over 47% of total expenses at Rs 467 crore. This spend was largely flat compared to Rs 455 crore in FY24. Upstox’s employee benefit expenses rose 11% year-on-year to Rs 211 crore, including Rs 13.6 crore in non-cash ESOP costs, while legal and professional expenses declined 8% to Rs 123 crore. Other overheads, including finance costs, depreciation and amortisation, travel, and miscellaneous expenses, pushed the company’s total expenses to Rs 991 crore in the last fiscal year, which grew 6% from Rs 935 crore in FY24. Overall, while Upstox’s revenue and expenses remained largely flat in FY25, a Rs 103 crore increase in non-operating income helped the company post a 21.5% rise in profit to Rs 215 crore, compared to Rs 177 crore in FY24. The company’s ROCE and EBITDA margin stood at -0.45% and 0.98% respectively in FY25, with a positive EBITDA of Rs 9 crore. As of March 2025, its current assets totaled Rs 4,029 crore, including a healthy cash and bank balance of Rs 2,744 crore. Upstox has raised over $200 million to date and was last valued at $3.5 billion. Data from startup intelligence platform TheKredible shows Tiger Global as the largest external shareholder with a 38.54% stake. Upstox competes with players such as Zerodha, Groww, and Angel One. In FY25, Zerodha reported revenue of Rs 8,847 crore with a profit of Rs 4,237 crore, while Groww posted a 50% year-on-year rise in revenue to Rs 3,902 crore. Angel One reported revenue of Rs 5,238 crore during the year.

Download the medial app to read full posts, comements and news.